Due to the emergence of Omicron subvariants that evade the effect of this drug’s two monoclonal antibodies, FDA withdrew the EUA (1/26/23).
The FDA issued an Emergency Use Authorization (EUA) permitting the emergency use of tixagevimab/cilgavimab for pre-exposure (PrEP) of COVID-19 in adults and pediatric patients (≥12 years of age and at least 40kg) who are not currently infected with SARS-CoV-2, have not had recent exposure to SARS-CoV-2.
AND
OR
Tixagevimab/cilgavimab is NOT indicated for:
PrEP is not a substitute for vaccination in individuals for whom vaccination is recommended. For individuals who have been vaccinated, tixagevimab/cilgavimab should be administered 2 weeks after vaccine administration.
There's more to see -- the rest of this topic is available only to subscribers.